Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Mendus AB (publ) is a biopharmaceutical company headquartered in Stockholm, Sweden, with additional offices in the Netherlands, specializing in the development of immunotherapies to combat tumor recurrence and enhance long-term survival for cancer patients. The company leverages dendritic cell biology to create off-the-shelf, cell-based products that activate the patient’s immune system against cancer and infectious diseases, prioritizing clinical efficacy alongside a favorable safety profile. Key programs include vididencel (formerly DCP-001), derived from the proprietary DCOne cell line and advancing in Phase II trials like ADVANCE-II and CADENCE for acute myeloid leukemia (AML), as well as Phase I ALISON for ovarian cancer; and ilixadencel, targeting established tumors through intratumoral immune priming in Phase 1/2 trials for soft tissue sarcomas. An NK cell program is also in preclinical development. Formerly Immunicum AB, Mendus rebranded in June 2022 following a 2020 merger and went public in 2013, positioning itself at the forefront of immunotherapy innovation in oncology. Led by CEO Erik Manting and supported by seasoned executives, a robust board, and a world-class Scientific Advisory Board, Mendus drives progress in cancer treatment through strategic alliances and ongoing clinical advancements.
kr 0.62
+kr 0.07 (+11.93%)
EOD Jun 23, 2026 · Twelve Data
Negative free cash flow of -kr 82M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 104M
▲ +11.8% YoY
Op. Margin
—
ROIC
-13.97%
▲ +0.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 87M
▼ -0.4% YoY
Op. Cash Flow (TTM)
-kr 87M
▼ -2.3% YoY
Net Debt
-kr 46M
Net Cash Position
Cash & Equiv.
kr 65M
Continue Research
Mendus AB (publ) (IMMU.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Mendus AB (publ) scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Mendus AB (publ) scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -14.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh IMMU.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.